title: [The value of biphosphonates in the therapy of prostate cancer].
abstract: Skeletal complications of bone metastases or secondary osteoporosis are a frequent event in patients with prostate cancer. Bisphosphonates have been widely used for both indications because of their capacity to prevent bone loss, to reduce pain and to inhibit metastatic growth. Possible side effects include acute phase reactions, osteonecrosis of the jaw and renal impairment. Therefore, the risks and benefits of therapy should be considered and informed consent obtained from the patient. Given current evidence the guidelines only allow a recommendation for use in patients with metastatic prostate cancer.
authors.affiliation: Abteilung für Urologie, Kinderurologie und Uro-Onkologie, St. Josef-Hospital, Hospitalstrasse 45, 53840, Troisdorf, Germany. norbert.rolfes@josef-hospital.de
authors.forename: N
authors.initials: N
authors.lastname: Rolfes
authors.forename: G
authors.initials: G
authors.lastname: Lümmen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: J Urol. 2003 Jun;169(6):2008-12
references.pmid: 12771706
references.citation: J Urol. 2006 Dec;176(6 Pt 2):S50-4
references.pmid: 17084167
references.citation: Cancer Invest. 2009 Feb;27(2):221-6
references.pmid: 19235596
references.citation: Cancer. 2007 Mar 15;109(6):1090-6
references.pmid: 17311345
references.citation: J Clin Oncol. 2008 Sep 20;26(27):4426-34
references.pmid: 18802155
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1588-94
references.pmid: 9362426
references.citation: J Clin Invest. 1996 Aug 1;98(3):698-705
references.pmid: 8698861
references.citation: J Urol. 2002 Feb;167(2 Pt 1):535-8
references.pmid: 11792913
references.citation: N Engl J Med. 2005 Jan 13;352(2):154-64
references.pmid: 15647578
references.citation: J Urol. 2002 May;167(5):1952-6
references.pmid: 11956415
references.citation: Cancer Res. 2001 Mar 15;61(6):2602-8
references.pmid: 11289137
references.citation: Gerontology. 2006;52(2):107-10
references.pmid: 16508318
references.citation: Cell Biol Int. 2009 Feb;33(2):239-46
references.pmid: 19103299
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72
references.pmid: 19531404
references.citation: Eur Urol. 2004 Dec;46(6):731-39; discussion 739-40
references.pmid: 15548440
references.citation: BMJ. 2003 Aug 30;327(7413):469
references.pmid: 12946966
references.citation: Eur Urol. 2008 Nov;54(5):1066-72
references.pmid: 18602738
references.citation: Eur Urol. 2006 Mar;49(3):429-40
references.pmid: 16431012
references.citation: Aktuelle Urol. 2009 May;40(3):169-70
references.pmid: 19479669